Avrupa Birliği - Letonca - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipeksola dihidrohlorīda monohidrāts - restless legs syndrome; parkinson disease - anti-parkinsona zāles - mirapeksīns ir indicēts idiopātiskas parkinsona slimības pazīmju un simptomu ārstēšanai atsevišķi (bez levodopas) vai kombinācijā ar levodopu i. slimības gaitā, caur nobeiguma posmā levodopa iedarbību pagaist vai kļūst par nekonsekventu un terapeitisko efektu svārstības notiek (beigu devu vai "on-off" svārstības). mirapexin ir norādīts simptomātiska ārstēšana vidēji smagas idiopātiska nemierīgs-kājiņas sindroms devas līdz 0. 54 mg, parastā (0. 75 mg sāls).

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imūnsupresanti - lūdzu, skatiet produkta informācijas dokumentu.

Letonya - Letonca - Adama

adama - suspensijas koncentrāts - azoksistrobīns - fungicīdi

Letonya - Letonca - Adama

adama - suspensijas koncentrāts - azoksistrobīns + tebukonazols - fungicīdi

Letonya - Letonca - Adama

adama - suspensijas koncentrāts - azoksistrobīns + ciprokonazols - fungicīdi

Letonya - Letonca - Adama

adama - emulsijas koncentrāts - prohlorazs - fungicīdi

Letonya - Letonca - Zāļu valsts aģentūra

bionorica se, germany - iris versicolor, caulophyllum thalictroides, cyclamen purpurascens, vitex agnus-castus, lilium tigrinum, strychnos ignatia - pilieni iekšķīgai lietošanai, šķīdums

Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

mirra-m - tablete

Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

fitness rock, sia 42103050578 uliha ielā 132-22, liepāja, lv – 3416 - tablete - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem